TickerTalks
Browse all tickers →
TickerTalks›$NWBO
NWNWBO

Northwest Biotherapeutics, Inc.

$NWBO·$263M·Biotechnology·Healthcare
$0.15+0.3%YTD-33.1%1Y-39.1%
Price updated 3h ago·X counts updated 2d ago
NWNWBO
$NWBONorthwest Biotherapeutics, Inc.
$0.15+0.33%1.1k posts1.2×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $NWBO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

1,056X posts · last 7 days
Sep 12Sep 27
Chatter Meter
1.2×
QuietNormal · 1×Loud

How loud $NWBO's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 95% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data52 posts analyzed · as of 2026-09-29

Sentiment is defiantly bullish, with the DCVax community rallying around fresh EANO trial data and a Saudi SPIMACO biotech MOU as evidence the science is unstoppable. The dominant emotion is anger, not doubt: holders are hammering the MHRA over a 1,000-day approval delay and pointing to naked shorting as the reason the stock sits near sixteen cents.

Read what X is saying about $NWBO

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NWBO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventEvent coming upAI verdict · as of 2026-09-28

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Northwest Biotherapeutics is a penny stock with a UK regulatory decision inside a live 30-day window and a Saudi MOU — binary outcomes on a 16-cent name.

Northwest Biotherapeutics is a penny-stock biotech developing DCVax-L, an immunotherapy for glioblastoma. The UK MHRA regulatory review is now roughly 1,000 days old with the approval decision window running from September 15 to October 16, and management just announced a Saudi manufacturing MOU to be signed at the Riyadh biotech summit.

  • The regulatory catalyst is real and dated: a UK marketing-authorization approval would be the first-ever regulatory greenlight for DCVax-L after a Phase 3 that hit its primary endpoint, unlocking commercial revenue on a business that generated $807K last quarter.
  • The commercial trajectory is contingent on approval: consensus revenue for 2027 is $39M (single analyst) — a giant step-up from today, and entirely dependent on the MHRA decision landing positive.
  • The share structure is the honest risk: 1.6B shares outstanding, a $4.9M ATM raise priced in July at $0.001 per share, and the stock at $0.16 near a 52-week low — dilution is real and ongoing while the catalyst plays out.

Watch daily for the MHRA decision through October 16 — a positive approval likely reprices this multiples higher; a rejection or a further review-clock extension pushes this back to the low teens of a cent range and forces another dilutive raise. Binary either way.

Agrees with X sentimentAgrees with the catalyst read — the MHRA window is dated and the SPIMACO MOU is real — but the 'active suppression' frame the base uses is the exact phrasing that appears at every OTC penny-stock catalyst wait; the tape is priced this low because of dilution history and open litigation, not just because someone's naked-shorting it.

What to watch: The MHRA approval decision window through October 16 is the whole event — a positive approval likely reprices this several multiples higher; a rejection or another review extension forces another dilutive raise.

On the calendar: 2026-10-16 — end of MHRA MAA approval window

Read the AI verdict on $NWBO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing DCVax personalized dendritic cell immunotherapy for glioblastoma and other cancers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NWBO.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $NWBO

Neutral — Clinical-stage biotech developing DCVax personalized dendritic cell immunotherapy for glioblastoma and other cancers.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.4%YTD
+48.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-129%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-35.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-16.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
197.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
62.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-44.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 14, 2026$-0.01——
Q1 2026May 15, 2026$-0.00——
Q1 2026Apr 15, 2026$0.00——
Q3 2025Nov 14, 2025$-18.22——
Next earningsThu, Nov 12

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$494K+31.7%-71.5%-2206%$-0.00$-12.6M
Q4 FY25$672K+190.9%-19.2%-2010%$0.00$-15.2M
Q3 FY25$200K-44.0%-161%-7160%$-0.02$-13.5M
Q2 FY25$131K-74.3%100%-11282%$-0.01$-7.0M

Forward consensus

2-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.6M$1.6M – $1.6M-$0.05-$0.05 – -$0.051
FY27$38.9M$38.9M – $38.9M-$0.07-$0.07 – -$0.071

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.6%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-11.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-28.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.6B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.615-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.ListedOTCListed on an over-the-counter market (PNK / OTCQB / OTCQX), not a major exchange. Lower disclosure requirements and thinner liquidity.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 318-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

Northwest Biotherapeutics, Inc. (NWBO) entered into financing with YA II PN, Ltd with a counterparty on 2026-07-31, involving $4.9 million. . This is a material definitive agreement (Item 1.01) requiring immediate disclosure under SEC rules. Investors should review the agreement terms for financial obligations, dilution, or strategic implications.

424B5Prospectus supplement (offering)Jul 31424B5
AI summary

NWBO (NWBO) filed a prospectus supplement (Form 424B5) on 2026-07-31 for an immediate offering of 40,325,000 Shares $0.001 per share, raising approximately $4.9 million. Use of proceeds: Use of Proceeds S–2 Dividend Policy S–2 Dilution S–2 Description of Securities S–3 Experts S&nda. This is dilutive capital activity happening now — new shares will be issued. Investors should assess pricing relative to market and stated use of proceeds to evaluate dilution impact.

8-KPress release / Reg FDJul 208-K — Item 7.01: Press release / Reg FD
AI summary

Northwest Biotherapeutics, Inc. (NWBO) filed a Reg FD disclosure (Item 7.01) on 2026-07-20, furnishing presentation were quite encouraging. Reg FD filings ensure simultaneous public disclosure of material information shared with select investors. This is generally informational; no new deal terms or financial results were announced unless otherwise noted. Investors should review the attached exhibit for updated guidance or strategic commentary.

8-KAcquisition completedApr 78-K — Item 2.01: Acquisition completed
+ 5 other (2 10-Qs · 1 EFFECT · 1 POS AM · 1 10-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Companygurufocus.com·55d agoNorthwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Companyprnewswire.com·55d agoNorthwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analysesprnewswire.com·83d agoNorthwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meetingprnewswire.com·89d agoNorthwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meetingprnewswire.com·89d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$AURA$ARCT$IBRX$NKTR$ABVX
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport